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Background: Spontaneous regression of hepatocellular carcinoma (HCC) is well documented, although
the aetiology of this phenomenon remains unknown.
Methods: A review of the English literature was performed for reports of spontaneous regression of
HCC. Reports were classified by mechanism based on the available information.
Results: Spontaenous regression of HCC has been identified in 75 patients. The most common mecha-
nisms of regression identified were tumour hypoxia (n = 21, 28.0%), a systemic inflammatory response
(n = 25, 33.3%) and unknown (n = 29, 38.7%). In patients where tumour hypoxia was described as
the aetiology, mechanisms included spontaneous hepatic artery thrombosis and sustained systemic
hypotension. In patients where a systemic inflammatory response was the aetiology, mechanisms
included cholangitis, trauma and elevated cytokine levels.
Discussion: Spontaneous regression of HCC is most commonly associated with tumour hypoxia or a
systemic inflammatory response. Determining the aetiology of spontaneous regression may identify
potential therapeutic pathways. Tumour hypoxia is already the basis of treatment modalities such as
hepatic artery embolization and the anti-angiogenic agent sorafenib. However, treatment modalities for
HCC do not currently include immune-directed therapies; this may prove to be a worthy target for future
research.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer in the world and results in over half a million deaths
annually.1 Unfortunately, most patients present with advanced
disease, at which point therapeutic options are limited. Even with
current treatments, the mortality of this disease is high with a
median survival shown in some studies to be as little as 20 months
after the onset of symptoms.2
Spontaneous regression of cancer was originally defined by
Everson and Cole3 in 1959 as being ‘the partial or complete
disappearance of a malignant tumour in the absence of all treat-
ment, or in the presence of therapy which is considered to be
inadequate to exert a significant influence on neoplastic disease’.
Spontaneous regression is a well-established phenomenon in
certain malignancies including renal cell carcinoma, neuroblas-
toma and choriocarcinoma.4 However, regression of HCC appears
to be a rare event, but has also been described.
In 1972, Johnson and colleagues5 first described spontaneous
regression of HCC in a 3-year-old girl who had developed
biopsy-proven HCC while on chronic androgen-anabolic steroid
treatment for aplastic anaemia. One year after her diagnosis, she
This manuscript is based on a poster presented at the AHPBA meeting,
Miami, 7–11 March 2012.
DOI:10.1111/j.1477-2574.2012.00478.x HPB
HPB 2012, 14, 500–505 © 2012 International Hepato-Pancreato-Biliary Association
was admitted to the hospital for treatment of Staphylococcus
aureus septicaemia at which time her imaging demonstrated near
complete resolution of her HCC. Other than her bacteraemia, the
only reported event in the patient’s condition was the cessation of
her steroid treatment.5 Since this initial report, within the English
literature, over 80 additional patients have been reported to have
undergone spontaneous regression of their HCC.
The true incidence of spontaneous regression of HCC is diffi-
cult to determine accurately, however, Oquinena and colleagues6
estimated this value by collating data from 10 randomized con-
trolled trials involving 1640 patients with HCC. Based on the
incidence of regression in the control groups, it was calculated to
be 0.4%.6
Several mechanisms have been suggested to explain the aetiol-
ogy of spontaneous regression of HCC, including the administra-
tion of herbal remedies,7–10 or the withdrawal of a possible
causative agent such as alcohol,11,12 tobacco,9 or exogenous andro-
gens.5,13 Two additional theories cited in the literature as possible
mechanisms of regression are (i) tumour hypoxia and (ii)
systemic inflammatory activation. These pathways have been
explored for their therapeutic effect in other malignancies as well.
One example of this is the use of interleukin-2 (IL-2) for the
treatment of melanoma, an agent which is known to be a potent
inducer of pro-inflammatory cytokines.14,15
The present study reviews the published literature on sponta-
neous HCC regression and attempts to classify these reports by
mechanism. Determining of the aetiology of spontaneous regres-
sion may help identify future therapeutic pathways for HCC
treatment.
Methods
A PubMed search of the English literature was performed using
the key words ‘regression’ and ‘hepatocellular carcinoma’. All
resulting articles were reviewed and assessed for inclusion. A
manual search was then performed on all references cited in these
publications. Spontaneous regression was defined as the reduction
in size or disappearance of a HCC, as determined radiologically or
pathologically in the absence of any possible direct effects from
standard treatments. Any reports that did not meet this definition
were excluded from further classification and analysis. A patient
from the local institution who underwent spontaneous regression
of their HCC and has not been previously reported was added to
the analysis (Fig. 1).
Once patients were assessed, they were categorized by mecha-
nism of regression into one of three categories: tumour hypoxia,
systemic inflammatory response and unknown or other. In some
instances the mechanism was proposed by the authors whereas in
others the report described a situation in which the aetiology
could clearly be categorized as either tumour hypoxia or activa-
tion of the inflammatory system.
Using the data available in the published reports, demographic
and clinical features were recorded, including age, gender, pres-
ence of cirrhosis, type of underlying liver disease (hepatitis B,
hepatitis C, alcoholic cirrhosis or other) and degree of tumour
response.When provided, survival time in months since the origi-
nal diagnosis was also recorded.
Statistical analysis was performed using SPSS version 17.0
(SPSS Inc., Chicago, IL,USA). The two cohorts of tumour hypoxia
and systemic inflammatory response were compared. For nominal
data where the denominator was incomplete the reduced figure is
provided. Univariate analysis was conducted in the standard
fashion using a Mann–Whitney U-test to compare continuous
non-parametric variables, and a chi-square test to compare cat-
egorical variables.
Results
The PubMed search of the English literature identified 84 patients
with spontaneous regression of HCC. Of these, 75 matched the
definition of ‘spontaneous’ as defined above. Nine patients were
excluded because regression occurred after the use of a standard of
care treatment directed at the primary tumour, including transhe-
patic arterial embolization (n = 4), systemic chemotherapy (n = 2),
radiofrequency ablation (n = 1) and the administration of mul-
tiple accepted treatment modalities (n = 2).
The mean age of patients with regression was 64 years [range
5–89, standard deviation (SD)  14]. Of the 75 patients, 73%
(50/70) were male. Seventy-five percent (43/57) had cirrhosis.
Information on underlying liver disease was present in 70 of the
patients, demonstrating 12 patients (17%) with hepatitis B, 32
patients (46%) with hepatitis C, 9 patients (14%) with alcoholic
cirrhosis and 17 patients (24%) with no known underlying
hepatic pathology. Information on the degree of tumour regres-
sion was available in 67 cases, of which 32 patients (48%) had a
partial regression, and the remaining 35 patients (52%) had a
complete regression.Median survival time from diagnosis of HCC
was 29 months (range 4–240).
Of the 75 patients with true spontaneous regression included in
this review, 21 (28.0%) could be attributed to tumour hypoxia and
25 (33.3%) to a systemic inflammatory response. Spontaneous
regression in the remaining 29 (38.7%) patients was as a result of
an unknown mechanism. Other than these categories, no other
mechanism was consistently suggested by more than two case
reports.
The ‘tumour hypoxia’ category16–36 included patients with an
occlusive portal vein thrombosis, spontaneous hepatic artery
thrombosis, angiospasm during angiography, development of a
large arterioportal shunt and a sustained period of hypotension
because of a massive gastrointestinal bleed (Table 1).
The ‘systemic inflammatory response’ category37–52 included
patients with cholangitis, a persistent febrile illness, bacteraemia,
the detection of elevated levels of cytokines and trauma leading to
bone fractures. Also included were patients in whom pulmonary
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metastases regressed after embolization of the primary lesion, or
where the primary hepatic tumour regressed after radiation of
bony metastases (Table 1).
The remaining patients were labelled as having an ‘other or
unknown’ mechanism.5,7–13,20,53–70 Some possibilities suggested by
the authors of reports in the unknown category included the use
of herbal medications, smoking cessation, alcohol cessation, with-
drawal of androgen therapy and administration of Vitamin K.
However, most of the reports in this group did not have any
mechanism of regression suggested.
The two cohorts of tumour hypoxia and systemic inflammatory
response were then compared. Univariate analysis did not show
any significant association of mechanism of regression with age,
gender, liver disease, cirrhosis, completeness of response or
survival time.
Discussion
Based on the current review of the literature, two common
mechanisms of spontaneous HCC regression were identified:
tumour hypoxia and systemic inflammatory activation.
Tumour hypoxia
The current analysis revealed multiple patients in which regres-
sion appeared to be associated with tumour hypoxia. Several
occurrences were related to occlusion of either the hepatic artery
or portal vein, which probably led to a direct ischaemic insult.
Other patients experienced profound systemic hypoperfusion,
such as sustained hypotension associated with a massive variceal
bleed. Tumour hypoxia as a mechanism is intuitively appealing in
that it mirrors established treatment modalities for HCC. For
example, both hepatic artery embolization and the agent sor-
afenib can be considered to rely upon the induction of tumour
hypoxia for their effect.71
Transhepatic arterial chemoembolization occludes the arterial
supply to the tumour72 and artificially produces a similar effect
to the reports of regression of HCC after spontaneous arterial
thrombosis. Sorafenib’s efficacy is based on the principle of ‘anti-
angiogenesis’ as described by Folkman in 1971.73 This small mol-
ecule is an inhibitor of several tyrosine kinases, including
several of the vascular endothelial growth factor receptors
whose downstream pathways have been shown to be overactive
in human HCC.74 This drug is thought to work by inhibiting
Figure 1 Computed tomography (CT) images of a 59-year-old male with spontaneous regression of hepatocellular carcinoma (HCC)
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neovascularization of the malignancy and as a result appears to
function in a manner that mimics the tumour hypoxia mecha-
nism of spontaneous regression.71
Systemic inflammatory response
However, tumour hypoxia does not explain all of the reported
patients with HCC, in particular those involving the regression of
metastatic disease. In these instances, a systemic process must be
the inciting factor underlying the spontaneous regression. Inter-
estingly, several reports documented the presence of elevated
cytokine levels, suggesting a systemic inflammatory response.
Abiru et al.37 noted elevated IL-18 in three patients with regression
of HCC. IL-18 has been shown to induce interferon (IFN)-gamma
production by T-cells and natural killer (NK) cells, thus poten-
tially producing enhanced cytotoxic activity targeted at cancer
cells. Jozuka et al.40 proposed a similar mechanism after they
detected elevated levels of NK cell activity, IL-2, IL-6, IL-12 and
IFN-gamma throughout the course of the patient’s spontaneous
regression.
While many patients with cytokine elevation were associated
with infections, high levels were also seen in non-infectious
patients. The report by Blondon et al.38 describes a patient in
whom tumour rupture and the peritoneal dissemination of cancer
cells led to the activation of an immune response against the
tumour antigens. In a report where regression of the primary
HCC tumour after radiation therapy delivered to metastases,49,52
the authors noted that tumour necrosis factor (TNF)-alpha was
elevated after radiotherapy and proposed that tumour lysis may
have led to activation of a host immune response directed at
tumour antigens.
Pathological evidence of an inflammatory mechanism for
regression was demonstrated in one patient where a biopsy of the
previous tumour site revealed the presence of a chronic inflam-
matory infiltrate.50 Wada et al.75 reported that patients with HCC
whose resected tumours demonstrated a lymphocytic infiltration
had a better prognosis than those without the infiltrate; the
authors attributed the improved survival to the anti-tumour effect
induced by cellular and humoral immunity. Together, these
reports provide reasonable support to the theory that a systemic
inflammatory response is associated with spontaneous regression.
In conclusion, of the 75 patients who underwent true sponta-
neous regression of HCC in the literature, 28.0% can be attributed
to tumour hypoxia and 33.3% to activation of a systemic inflam-
matory response. Although the current findings suggest that
tumour hypoxia and the inflammatory response are important
components of spontaneous regression, the true mechanism of
regression is certainly multifactorial and complex. There are
likely interactive effects between these two phenomena and
other causative elements which together lead to regression. These
possible aetiologies of tumour regression hint at intriguing
methods of treating HCC. Tumour hypoxia is already the basis of
treatment modalities such as hepatic artery embolization and the
anti-angiogenic agent sorafenib. Treatment modalities for HCC
do not currently include immune-directed therapies but this
is an active area of research. Future publications of spontaneous
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